The need for sustained-release glaucoma therapies is clear to anyone caring for patients with the disease. Our conventional topical therapies have a number of toxic effects on the external ocular tissues. There are physical and medical limitations to eye drop instillation in our generally older patient population. The time and scheduling demands of drop instillation and pharmacy visits are intensive. And the cost associated with bottle therapy, especially in cases of spillage and premature refills, can be prohibitive over the long term. These barriers negatively affect adherence and long-term control of the disease, increasing risk for glaucomatous progression and irreversible vison loss. Potential sites of implantation for novel sustained-release therapies include the ocular surface, the eyelid puncta, the subconjunctival space, the anterior chamber and within the trabecular meshwork.